Novartis AG vs F. Hoffmann-La Roche AG: Strategic Comparison

This in-depth comparison examines Novartis AG and F. Hoffmann-La Roche AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novartis AG on its own, evaluating F. Hoffmann-La Roche AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novartis AG and F. Hoffmann-La Roche AG is widest.

On the headline numbers, Novartis AG reports annual revenue of $56.7B against ~$73.8B for F. Hoffmann-La Roche AG, while their respective market capitalizations stand at $275.3B and $355.0B. Novartis AG is headquartered in Switzerland and F. Hoffmann-La Roche AG operates from Switzerland, and those different home markets shape how each company competes.

Novartis AG: Novartis is one of the world's largest drugmakers by sales and the larger of Basel's two pharmaceutical groups alongside Roche. Created by the 1996 merger of Ciba-Geigy and Sandoz, it shed eye care (Alcon, 2019) and generics (Sandoz, 2023) and now sells only innovative medicines. Its best-known products include Entresto for heart failure, Cosentyx for psoriasis and arthritis, Kisqali for breast cancer, Kesimpta for multiple sclerosis and Pluvicto for prostate cancer.

F. Hoffmann-La Roche AG: Roche Holding AG is a Swiss healthcare company headquartered in Basel and listed on the SIX Swiss Exchange (ROG non-voting equity securities and RO bearer shares; RHHBY ADRs in the US). It is one of the largest pharmaceutical companies by sales and the largest in vitro diagnostics supplier. Key subsidiaries include Genentech in the US, Chugai Pharmaceutical in Japan and Foundation Medicine.

Novartis AG and F. Hoffmann-La Roche AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novartis AG and F. Hoffmann-La Roche AG.

Novartis AG business model: Novartis earns almost all of its revenue by selling patented prescription medicines to wholesalers, hospitals, pharmacies and national health systems in about 140 countries. FY2025 net sales of $54.5 billion came from four core areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology) plus established brands. The model depends on reinvesting roughly a fifth of sales into R&D and acquisitions so that new launches replace drugs losing exclusivity. Since the 2023 Sandoz spin-off, Novartis has no generics business; it also earns smaller "other revenues" (about $2.1 billion in 2025) from royalties and milestones.

F. Hoffmann-La Roche AG business model: Roche makes money in two ways. The Pharmaceuticals Division (~$57.2 billion (CHF 47.7 billion) in 2025) sells patented medicines, mostly biologics, in oncology, neuroscience, immunology, ophthalmology and haemophilia; top growth drivers in 2025 were Phesgo, Xolair, Ocrevus, Hemlibra and Vabysmo. The Diagnostics Division (~$16.6 billion (CHF 13.8 billion)) places cobas, Elecsys and Ventana instruments in laboratories and earns recurring revenue from the reagents, tests and service contracts needed to run them. Companion diagnostics link the two: a Roche test can identify the patients most likely to benefit from a Roche drug.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novartis AG stack up against those of F. Hoffmann-La Roche AG.

Novartis AG competitive advantage: Novartis's edge rests on scale in late-stage development and specialist platforms that are hard to copy. It owns the leading commercial radioligand therapy franchise (Pluvicto and Lutathera) along with dedicated isotope manufacturing sites in the US and Europe, an siRNA cardiovascular drug (Leqvio), and, since February 2026, Avidity Biosciences' antibody-oligonucleotide conjugate platform. Its FY2025 core operating margin of about 40% and free cash flow of $17.6 billion fund buybacks, dividends and bolt-on deals simultaneously.

F. Hoffmann-La Roche AG competitive advantage: Roche's edge comes from three things: scale in both drugs and diagnostics, a long-horizon ownership structure, and a federated R&D model. The Hoffmann and Oeri family pool holds the majority of voting shares, which shields management from takeover pressure. Research runs through separate centres (Genentech gRED in South San Francisco, pRED in Basel and majority-owned Chugai in Japan), and the company spent ~$14.6 billion (CHF 12.2 billion) on core R&D in 2025.

Future prospects matter as much as current results. The growth strategies below explain how Novartis AG and F. Hoffmann-La Roche AG each plan to expand from here.

Novartis AG growth strategy: Novartis concentrates on four therapeutic areas and on the US, its largest market. It pairs internal research with bolt-on acquisitions of late-stage or platform biotechs: Chinook (2023, kidney disease), MorphoSys (2024, myelofibrosis), Kate Therapeutics (2024, gene therapy capsids) and Avidity Biosciences (closed February 27, 2026, about $12 billion, neuromuscular RNA medicines). It is also expanding US manufacturing, including radioligand production capacity.

F. Hoffmann-La Roche AG growth strategy: Roche is building a cardiovascular, renal and metabolic franchise through acquisitions of Carmot Therapeutics (2023, $2.7 billion upfront) and 89bio (2025, up to about $3.5 billion), the petrelintide partnership with Zealand Pharma, and a new Innovation Center in Boston opened in September 2026. It is also extending its immunology pipeline via Telavant (2023, $7.1 billion) and investing in AI diagnostics with the PathAI acquisition announced in May 2026 ($750 million upfront plus up to $300 million in milestones).

A closer look at the financial trajectory of Novartis AG and F. Hoffmann-La Roche AG rounds out the comparison.

Novartis AG: Novartis grew FY2025 net sales 8% to $54.5 billion with a core operating margin above 40% and free cash flow of $17.6 billion. 2026 is a reset year: US generics of Entresto and Promacta cut Q1 2026 net sales 5% at constant currencies to $13.1 billion and core operating income 14%. Q2 2026 net sales rose 1% cc to $14.4 billion with a 41.2% core margin, though net income fell 19%. Management guides for low single-digit sales growth and a low single-digit decline in core operating income for 2026 at constant currencies.

F. Hoffmann-La Roche AG: Roche's 2025 group sales were ~$73.8 billion (CHF 61.5 billion), up 7% at constant exchange rates but only 2% in Swiss francs. Core operating profit grew 13% CER to ~$26.2 billion (CHF 21.8 billion), core EPS was CHF 19.46, and IFRS net income jumped to ~$16.6 billion (CHF 13.8 billion) from ~$11 billion (CHF 9.2 billion) in 2024, when impairments depressed profit. In H1 2026 core operating margin widened 1.7 points to 39.0%, while a strong franc pushed reported sales down 2%. The board raised the dividend to CHF 9.80, the 39th consecutive increase, and guided for mid-single-digit CER sales growth and high-single-digit core EPS growth in 2026.